Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Myasthenia gravis (MG) is a rare, chronic autoimmune disorder that disrupts the communication between nerves and muscles. It typically leads to symptoms such as muscle weakness, drooping eyelids, ...

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis. The Food and Drug Administration (FDA) has approved Imaavy ...

Highlights in myasthenia gravis (MG) from the American Academy of Neurology 2025 Annual Meeting include new therapy trials and practice reviews, as discussed by Dr Nicholas Silvestri of the ...

Myasthenia gravis is termed a rare disease, but several pharma companies are battling for the market of more than 70,000 Americans with the neurological disorder. Titled “Imagine Your Zillions ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Imaavy plus standard of care led to improvements at ...

The Ministry of Food and Drug Safety noted on the 24th that it will approve the use of the systemic Myasthenia Gravis treatment, Listigoju (Rozanolixizumab). Myasthenia Gravis is a rare disease ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...

PHOENIX, March 31, 2025 /PRNewswire/ -- More than 500 members of the myasthenia gravis (MG) rare disease community will come together this week in-person and virtually at the MGFA National ...

Myasthenia gravis (MG) is a chronic autoimmune condition that affects signaling between the body’s nerves and muscles, leading to muscle weakness. Symptoms of MG can appear anywhere on the body ...

With that said, there is one program I want to zero in on, which is the development of its differentiated CD-19 CAR-T being developed to target patients with Myasthenia Gravis [MG]. The reason why ...

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of Daily Living score compared to placebo at week 26. Results from the Phase III ...